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ABSTRACT 
Backgrounds: The prevalence of NAFLD is increasing in the world. The mechanism 
of pathogenesis and severity has not been clearly understood. Metabolic syndrome and 
some biomarkers though to play a role in incidence and severity of NAFLD. Objective: 
To clarify the role of the metabolic syndrome and biomarkers: insulin resistance, 
adiponectin, plasma levels of TNF-α in the incidence and severity of NAFLD. We 
calculate diagnostic value of the metabolic syndrome with biomarkers and liver 
function test as non-invasive method of diagnosis severity of NAFLD. Methods: 
Conducted a case control study for risk factors of NAFLD and cross-sectional study for 
the diagnostic test severity of NAFLD.  Cases were NAFLD patients and healthy 
subjects as controls. NAFLD diagnosis and severity classification based on liver biopsy 
with NAFLD activity score (NAS). Metabolic syndrome and insulin resistance 
evaluated based on IDF classification and HOMA IR index. Levels of insulin, 
adiponectine, and TNF-α were measured by ELISA. Results: Eighty cases and 75 
healthy controls were included in the study. The independent risk factors for NAFLD 
significantly were hypo-adiponectinemia, metabolic syndrome, of insulin resistance 
and high plasma levels of TNF-α consecutively. Hypo-adiponectinemia was proven as 
independent risk factor and might be potential as diagnostic test severity of NAFLD 
while the metabolic syndrome, insulin resistance, high plasma levels TNF-α, were not 
proven as risk factors severity of NAFLD Conclusions: The presence of metabolic 
syndrome, insulin resistance, hypo-adiponectinemia high levels of plasma TNF-α was 
risk factors of NAFLD, while hypoadiponectinemia was proven to be risk factor and 
might be as diagnostic test severity of NAFLD.  
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Non-Alcoholic Fatty Liver Disease (NAFLD) 
was the spectrum of lesions in the liver that 
showed hepatic component of the metabolic 
syndrome (type 2 diabetes, insulin resistance, 
dyslipidemia, and hypertension). NAFLD is 
typically characterised by steatosis 
macrovesicular, from simple steatosis to the 
inflammation and persistant lesion will progress 
into fibrosis and cirrhosis.(1)(2)(3) 
Several studies indicated that the prevalence 
rate of NAFLD and NASH have increased ranging 
from 17 to 33% for NAFLD and 5.7 to 17% for 
NASH.(4) Hasan Irsan (2002) reported that 
NAFLD was found in 30% of the population  in 
Jakarta (5) In dr. Kariadi Hospital Semarang, the 
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number of patients with fatty liver has increased 
by the year. The percentage of fatty liver was  4% 
in 2005, 4,5% in 2006, 5%  in 2007,  6%  in 2008 
and 7% in 2009.(6) The prevalence is expected to 
increase in accordance with increasing population 
of obesity, metabolic syndrome, and development 
of diabetes. 
NAFLD severity is defined as the most severe 
form of NAFLD with histopathology showing 
NASH  characterized by fatty infiltration of 
lobular inflammation, hepatocyte ballooning with 
or without fibrosis (NAFLD activity score ≥ 5).(7) 
Currently NAFLD progression is also associated 
with various complications outside the liver. 
Cardiovascular complication is one of the many 
conditions associated with NAFLD.(8) 
Pathogenesis of NAFLD have not yet clearly 
understood. The currently accepted explanation is 
the "Multiple hits hypothesis". Metabolic 
syndrome and several biomarkers such as: insulin 
resistance, adiponectin, plasma levels of TNF-α  
and polymorphisms of promoter gene of TNF-α 
may be involved.(9)(10)(11)(12)  
Recent studies indicated that 
hypoadiponectinmia was responsible for the 
hepatic fat accumulation and insulin resistance. 
Complexity of NASH pathogenesis involves 
reciprocal role between adiponectin and 
proinflammatory cytokines produced by 
mononuclear cells of peripheral blood and 
infiltration of lymphocytes and macrophages, 
which are embedded in white fat tissue.(10)(13) 
Insulin resistance is a major mechanism in the 
pathogenesis and progression of NAFLD. 
However, only a minority of patients with risk 
factors for NAFLD develop NASH, fibrosis and 
cirrhosis. It was still unclear why not all patients 
with insulin resistance develop NASH, allegedly 
specific changes in the liver responsible for the 
development of fatty accumulation and 
progression to inflammation. Studies in families 
suggest that genetic factors have a role in 
determining susceptibility to NASH.(14)(15)(16)  
The role of TNF-α in NAFLD is crossroad of 
many pathogenic pathways. Specific differences 
between patients with hepatic steatosis and 
NASH is the serum level of TNF-α, which is 
usually higher in patients with NASH. However, 
this difference did not always reach statistical 
significance.(14) 
The roles of metabolic syndrome and several 
biomarkers, such as insulin resistance, 
adiponectin, plasma levels of TNF-α in the 
pathogenesis of NASH require further 
investigation. 
Aim of this study was to clarify the roles of 
metabolic syndrome, insulin resistance, 
adiponectin and plasma levels of TNF-α as risk 
factors for the presence and severity of NAFLD, 
and to analyze the diagnostic value of the 
metabolic syndrome with several biomarkers as 
non-invasive methods of diagnosis and early 
detection of NASH. 
 
MATERIALS AND METHODS 
Study designs were case-control to clarify risk 
factors of NAFLD and cross sectional for 
diagnostic test of NASH.  Study was held in 
outpatient clinic of dr. Kariadi General Hospital 
Semarang on January 2009 – December 2011.  
Inclusion criteria for case group includes: aged 
> 14 years old having metabolic syndrome 
components and proven to have NAFLD based on 
abdominal ultrasound. Subjects will be excluded 
if known to have hepatitis A, B, C virus infection 
(AST and ALT > 5 times higher than normal with 
positive IgM anti HAV or positive HBsAg or 
positive anti HCV); autoimmune hepatitis 
(positive ANA test); alcoholic hepatitis; history of 
alcohol consumption (> 30 gr/ day for male and > 
20 gr/day fpr female); history of taking drugs 
causing fatty liver (glucocorticoid, estrogen, 
tamoxifen, amiodarone, metothrexate, valproate, 
diltiazem).  
Inclusion criteria for control group includes no 
history, and clinical symptoms of liver disease 
(with normal AST and ALT, negative HbsAg, 
negative anti HCV) and no liver abnormality 
found on abdominal ultrasound. Subjects will 
excluded if known to have liver disease by 
anamnesis, physical examination and laboratory 
findings; hepatitis virus infection (A,B,C); 
autoimmune hepatitits, alcoholic hepatitis; 
history of alcohol consumption; and history of 
taking drugs causing fatty liver.  
Histopathology of liver biopsy in classification 
according to NAS (NAFLD activity score) was 
performed in case group to assess the diagnosis 
and severity of NAFLD.(7) Diagnosis of metabolic 
syndrome was based on IDF classification,(17)(18) 
insulin resistance by index HOMA IR,(17)(18) 
measurement of the levels of insulin, adiponectin, 
and TNF-α using ELISA method.(19)(20)(21) 
 
RESULTS 
Clinical characteristics 
During the study period 80 NAFLD cases and 75 
controls were enrolled. To analyze risk factors for 
NAFLD, only 75 subjects in each group were 
involved in the study (figure 1). Analysis for 
severity of NAFLD involved all 155 subjects 
(figure 1).   
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Characteristic distribution of 
subjects in case and control groups were 
showed sex, age years   and height did not 
differ significantly between both groups. 
(44,7 ±10,28 vs 44,3 ± 9,98 years old, 
162,1±8,37  vs 161,1±6,31 Cm). Mean weight, 
body mass index and waist circumference of 
subjects in case group was found significantly 
higher than that of control group 77,0 (54,0 - 
115,0) vs 56,0 (41,0 - 74,0) kg,  29,0 (22,0 -  
47,4)  vs  22,5 (17,3 - 27,5)kg/M2,  99,0 (77,0 - 
134,0) vs 80,0  (64,0 - 98,0) cm (p< 0,001) 
consecutively. 
 
Metabolic syndrome and several 
biomarkers of NAFLD  
Distribution level of 5 components 
metabolic syndrome (waist circumference, 
blood pressure, fasting blood glucose , HDL 
cholesterol, fasting triglyserides ) in case and 
control groups were significantly different 
(p<0,001). There was a significant 
relationship between each MS component 
and the frequency of NAFLD incidence (p 
<0.001). The majority of subjects in the case 
group (77.0%) had central obesity, 83.8% 
hypertension, 100% fasting blood glucose> 
100 mg / dl, 78.6% low-level HDL cholesterol 
and 87.3% hypertriglyceridemia. Based on 
the number of MS components in the case 
group with MS, most (42.1%) had four, 44.4 
% had three and 17.5% had 5 MS 
components. Presence of insulin resistance 
was greater significant in cases (86,2%) 
compared to the control (13,8%) group. 
(p<0,001) Median HOMA-IR index and 
insulin level in case group were higher than 
that of control group, 3,67 (0,40-29,00) vs 0,62 
(0,02-23,58) , 12,40 (0,80-116,56) uIU/ml vs 
2,74 (0,09-86,95) uIU/ml consecutively. 
Statistical test showed a significant 
correlation between insulin resistance status 
and presence of NAFLD (p <0,001). 
Mean plasma levels of TNF-α in case 
group was significantly higher than in 
control group 7,98 (0,00 - 332,56) vs 2,24 (0,04 
-77,65) pg/ml (p <0,001), while mean serum 
level of adiponectin in case group was 
significantly lower than that of control group, 
2148,40 (493,80-9766,40) vs 8351,20 (1080,50 
- 22364,00) (p <0,001). Cut off level for TNF-
α and adiponectin as risk factors for incidence 
of NAFLD was > 3645 ng /cc, and < 4512 ng/cc 
respectively. There was significant 
correlation between serum levels of TNF-α 
and adiponectin with incidence of NAFLD (p 
<0,001). 
 
Risk factors of incidence of NAFLD 
Metabolic syndrome, insulin resistance, 
level of TNF-  and adiponectin were 
analyzed for risk factors of incidence of 
NAFLD. With 95% confidence interval, all 
four variables were statistically significant as 
risk factors for the incidence of NAFLD. 
Highest to lowest odds ratio (OR) 
consecutively were level of adiponectin < 
4511,94 ng/ml, OR 60,4 (21.4 - 170.4), 
presence of metabolic syndrome, OR 44,3 
(15.5-126.8), presence of insulin resistance, 
OR 21,6 (9.1-51.6) and high level of TNF-  
>3,645 pg/ml,OR 10,8 (5.1-23.0).  
Multivariate regression test for risk 
factors of NAFLD was performed as shown in 
table 1. Adiponectin < 4511,94 ng/ml and 
metabolic syndrome were two biggest risk 
factors for the incidence of NAFLD with 
adjusted OR 35,5 and 25 respectively
 
Analysis for severity of NAFLD (n=155) 
155 subjects: 
29 NASH, 40 suspected NASH, 11 simple 
steatosis, 20 with central obesity, 55 without 
central obesity 
Case control for risk factors of NAFLD (n=150) 
150 subjects: 
75 case subjects 
75 control subjects 
75 subjects 
without NAFLD 
106 subjects 
with NAFLD 
26 NAFLD subjects 
were excluded 
5 NAFLD subjects were not 
included in case control study 
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Table 1. Analysis of multivariate regression test for risk factor for NAFLD 
Risk factors Crude§ 
OR 
Adjusted OR  
(95% confidence interval) 
p* 
Metabolic syndrome 44,3 25,0 (4,7 - 133,6) < 0,001 
Insulin resistance 21,6 12,4 (2,5 - 61,8) 0,002 
TNF- α > 3,645 5,0 6,1 (1,3 - 19,9) 0,020 
Adiponectin < 4511,94 60,4 35,5 (7,5 - 167,5) <0,001 
§ OR from bivariate test 
  OR from multivariate logistic regression test 
* p value of  multivariate logistic regression test 
Severity of NAFLD 
Severity of NAFLD was based on Histological 
Scoring System for Non Alcoholic Fatty Liver 
Disease Score and Fibrosis Staging (NASH 
activity score = NAS). Histopathology biopsy of 
the liver was performed in all subjects in case 
group (75 subject) and the results were NASH 
(38,7%), Possible NASH (50,7%) and Simple 
Steatosis (10,6 %). Simple steatosis and possible 
NASH in case group combined with the normal 
healthy control group were later categorized as 
non NASH.  
 
Risk factors of severity of NAFLD 
Bivariate analysis showed all clinical 
characteristics and biomarkers had significant 
correlation with severity of NAFLD (incidence of 
NASH) (table 2). Further multivariate regression 
test revealed that the most significant 
parameters correlated to the severity of NAFLD 
were adiponectin <2230,50 ng/ml, Exp(B)=11.5 
(3.2-41), p=0.000, ALT >59,5 IU/L, Exp (B) = 8.6 
(2.8-26), p =0.000 and waist circumference >95,5 
cm, Exp(B) = 6.0 (1.8-20)p=0.003 
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Table 2. Correlation between clinical characteristic, biomarkers and severity of NAFLD 
Clinical characteristic and 
biomarker  
Group 
p* NASH 
n=29 
n (%) 
Non NASH 
n=126 
n (%) 
Waist circumference (cm)    
- >94,5  23 (39,7%) 35 (60,3%)  
- ≤94,5 6 (6,2%) 91 (93,8%) <0,001 
Fasting blood glucose (mg/dL)    
- > 102,5 16 (28,1%) 41 (71,9%)  
- ≤102,5 13 (13,3%) 85 (86,7%) <0,020 
Triglycerides (mg/dL)    
- >142,5 23 (32,4%) 48 (67,6%)  
- ≤142,5 6 (7,1%) 78 (92,9%) <0,001 
HDL (mg/dL)    
- <43,5 23 (30,3%) 53 (69,7%)  
- ≥43,5 6 (7,6%) 73 (92,4%) <0,001 
ALT  (IU/L)    
- >59,5 20 (54,1%) 17 (45,9%)  
- ≤59,5 9 (7,6%) 109 (92,4%) <0,001 
AST (IU/L)    
- >27,5 24 (37,5%) 40 (62,5%)  
- ≤27,5 5 (5,5%) 86 (94,5%) <0,001 
Homa IR    
- >2,21 23 (34,8%) 43 (65,2%)  
- ≤2,21 6 (6,7%) 83 (93,3%) <0,001 
TNF-α (ng/mL)    
- >9,41 18 (39,1%) 28 (60,9%)  
- ≤9,41 11 (10,1%) 98 (89,9%) <0,001 
Adiponectin (ng/mL)    
- <2230,50 25 (44,6%) 31 (55,4%)  
- ≥2230,50 4 (4,0%) 95 (96,0%) <0,001 
* x2 test    
 
 
 
 
Biomarkers Roles in Non-Alcoholic Fatty Liver Disease 
143 
 
 
Risk factor of severity of NAFLD was analyzed by 
comparing several risk factors: metabolic 
syndrome, insulin resistance, level of TNF-α and 
adiponectin. All parameters were statistically 
significant as risk factors of severity of NAFLD 
with prevalence ratio as listed in table 3.
 
Table 3. Analysis for risk factor of severity of  NAFLD 
Risk factors  
Group 
Prevalence ratio 
(95% confidence 
interval) 
p NASH 
n=29 
n (%) 
Non NASH 
n=126 
n (%) 
Metabolic syndrome 
(MS)     
- MS (+) 23 (35,9%) 41 (64,1%) 5,4 (2,3 - 12,6) < 0,001* 
- MS (-) 6 (6,6%) 85 (93,4%)   
Insulin resistance (IR)     
- IR (+) 23 (34,3%) 44 (65,7% 5,0  (2,2 - 11,7) < 0,001* 
- IR (-) 6 (6,8%) 82 (93,2%)   
TNF- α (pg/mL)     
- > 9,41 18 (39,1%) 28 (60,9%) 3,9  (2,0 - 7,5) < 0,001* 
- ≤ 9,41  11 (10,1%) 98 (89,9%)   
Adiponectin (ng/mL)     
- < 2230,50 25 (44,6%) 31 (55,4%) 11,0 (4,0 -  30,1) < 0,001* 
- ≥ 2230,50 4 (4,0%) 95 (96,0%)   
* x2 test 
 
Multivariate regression test for risk factor of 
severity of NAFLD is shown that Matabolic 
syndrome  Adj OR (95% CI) 3.3 (0.9-11.5), p = 
0.060, HomaIR  >2.21  AdjOR 1.4 (0.4-4.8), p = 
0.600, TNF-TNF- α > 9,41, AdjOR 1.6 (0.5-4.5) , 
p=0.400, and Adiponectinin < 2230,50 ng/ml, 
AdjOD 9,6 (2,6 - 34,4),p=0.001.  Based on the test 
result, adiponectin < 2230,5 ng/ml was the most 
significant risk factor of severity of NAFLD. 
Results of analysed among clinical characteristic 
and biomarkers for diagnostic test severity of 
NAFLD (presence of NASH) proved that  
adiponectin < 2230 ng/ml has Sensitivity 86 %, 
Specificity 75%, Positive predictive value 45%, 
Negative predictive value 96 %, and Accuracy 
77%. 
 
DISCUSSION 
This study proved the presence of metabolic 
syndrome, insulin resistance, low adiponectin 
levels, high plasma levels of TNF-α as 
independent risk factors for the incidence of 
NAFLD. Various studies have shown that 
obesity, type 2 diabetes, dyslipidemia, 
hypertension and insulin resistance (metabolic 
syndrome) were associated with NAFLD.(2,3,23) 
Multiple hit hypothesis that explained the 
pathogenesis of simple fatty liver to the 
occurrence of progression to inflammation 
(NASH, fibrosis and cirrhosis) involves  thorough 
metabolic syndrome components. The first hit is 
the presence of fatty liver as results from 
imbalance formation and breakdown of 
triglycerides.(22)(23)(24)(25)(26) Mitochondrial 
dysfunction is likely; disorder of beta-oxidase in 
mitochondria is the main cause of fatty liver. 
Insulin resistance is a key abnormality 
underlying the metabolic syndrome, and 
progression to NASH. Insulin resistance will 
enable secretion of several adipocytokines (TNF- 
α, IL-6), if excessive will be dangerous for the liver 
tissue, changes the speed and transports 
triglyceride synthesis in hepatocytes and finally 
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increases lipolysis in adipose tissue that causes 
exposure to the liver tissue with more free fatty 
acids.(15)(22)(27) 
Other factors such as inflammatory and 
oxidative stress will aggravate the progression of 
fatty liver to NASH, fibrosis, and necrosis. 
Metabolic syndrome is closely related to 
inflammation and oxidative stress conditions, 
individuals with metabolic syndrome, there were  
an increase in lipid peroxidation, IL-6, some 
adipocytokine eg TNF- α, reactive oxygen species 
(free radicals)  decrease of adiponectin, and will 
activate stelate cells and liver     
fibrogenesis.(2)(3)(27) 
Multivariate analysis of risk factors for 
the severity variables of NAFLD showed that only 
adiponectin which was proven to be an 
independent risk factor of severity of NAFLD. In 
accordance with these results, Hui et al (2004) 
also reported that adiponectin levels of NASH 
patients were significantly lower compared to 
patients with simple fatty liver,(28) although 
there were  differences in the criteria used 
NAFLD degrees where the Hui, et al using Brunt 
criteria and this study used NAFLD activity score 
(NAS). Another study by Lemoine et al (2009) also 
reported a significant difference in adiponectin 
levels between NASH group with simple fatty 
liver.(29) 
 Adiponectin concentrations decreased in 
patients with obesity, insulin resistance, and type 
2 DM and NAFLD, correlated negatively with the 
degree of fatty liver(30)(31) Hyperinsulinemic 
condition will lower adiponectin receptor 
expression and biological activity. Adiponectin 
has anti-lipogenic effects that would protect non-
adipose tissues such as liver and muscle. 
Adiponectin was hepatoprotective by increasing 
the sensitivity of liver cells to insulin, which leads 
to increased adenosine monophosphat protein 
kinase (AMPK) activity of fatty acid oxidation and 
the inhibition of the inflammatory process and 
lowering sterol regulatory element,(32)(33) 
hepatic cell proliferation and increased apoptosis 
thus lowering severity NAFLD and antagonists 
against TNF-α .(34)(35)(36) Decrease in 
adiponectin causes an increase of inflammatory 
response characterized with the increased of 
TNF-α level and fibrosis of the liver 
tissue.(34)(35)(36)(37)(10) 
Adipose tissue is a major presence of 
macrophage accumulation as the main source of 
local expression of TNF-α.(37) TNF- α is one of 
adipocytokine known to have antagonistic effects 
with adiponectin and contribute to insulin 
resistance, and recent studies have also alleged 
role in the metabolic syndrome and the 
progression / severity of NAFLD.(10)(38)   TNF- α 
in animal model  proved to play an important role 
in obesity and insulin  resistance, there was also 
a link between levels of TNF- α and  
mitochondrial dysfunction that  underlying liver 
abnormalities in NAFLD and NASH..(14)(39) 
This study suggest that adiponectin may 
potential it is a non-invasive diagnostic 
parameter for determining the existence of 
NASH. Although liver biopsy is the gold standard 
for diagnosis NASH, not easily be done in clinical 
practice for a variety of reasons accompanying. 
Expected future examination of adiponectin may 
be one option for diagnosis NASH. 
 
CONCLUSION 
This study showed that the risk factors proven 
to influence the incidence of NAFLD were 
metabolic syndrome, insulin resistance, plasma 
adiponectin levels <4511 ng / ml, plasma of TNF- 
α levels  > 3,645 pg / ml consecutively. 
Risk factors proven to affect the severity of 
NAFLD / NASH events in patients with simple 
fatty liver was plasma adiponectin levels <2330,5 
ng / ml, whereas metabolic syndrome, insulin 
resistance, plasma levels of TNF- α > 9,41 pg / ml 
were not proven statistically. Plasma adiponectin 
levels <2230,5 ng / ml have potential can be used 
as a non-invasive diagnostic tests of NASH. 
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